Mitochondrial toxicity and HIV therapy

Sexually Transmitted Infections

Volumn 77, Issue 3, 2001, Pages 158-173

  White, A J ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

HIV therapy; Mitochondrial toxicity

Indexed keywords

DIDANOSINE; MITOCHONDRIAL DNA; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

CARDIOMYOPATHY; CELL DIVISION; CELL HETEROGENEITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG ACTIVATION; DRUG DISTRIBUTION; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; LIPODYSTROPHY; MITOCHONDRIAL MYOPATHY; NEPHROTOXICITY; NEUROPATHY; PANCREATITIS; PRIORITY JOURNAL; REVIEW; SEGREGATION ANALYSIS;

ACIDOSIS, LACTIC; DNA, MITOCHONDRIAL; HEMATOLOGIC DISEASES; HIV INFECTIONS; HUMANS; LIPODYSTROPHY; MITOCHONDRIA; MITOCHONDRIA, HEART; MITOCHONDRIAL MYOPATHIES; PANCREATITIS; PERIPHERAL NERVOUS SYSTEM DISEASES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0034956253     PISSN: 13684973     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.77.3.158     Document Type: Review

References (167)

1. Antiretroviral therapy and the lipodystrophy syndrome
2. DNA polymerases versus HIV reverse transcriptase in AIDS therapy
3. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway
4. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: Lactic acidosis, risk factors and therapeutic options
5. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: A looming obstacle for long-term antiretroviral therapy?
6. The mitochondrial genome: Structure, transcription, translation and replication
7. Mitochondrial genetics: Principles and practice
8. Lactic acidosis and other mitochondrial disorders
9. Cloning and characterization of the human mitochondrial DNA polymerase, DNA polymerase gamma
10. Mitochondrial DNA polymerase gamma is expressed and translated in the absence of mitochondrial DNA maintenance and replication
11. New features of mitochondrial DNA replication system in yeast and man
12. Genetic integrity of the mitochondrial genome
13. Mitochondrial respiratory chain disorders I: Mitochondrial DNA defects
14. Mitochondrial respiratory chain disorders. II: Neurodegenerative disorders and nuclear gene defects
15. Mitochondrial DNA and disease
16. Deoxyribonucleotide analogs as inhibitors and substrates of DNA polymerases
17. The HIV-1 transactivator protein Tat is a potent inducer of the human DNA repair enzyme β-polymerase
18. A comparison of three nucleoside analogs with anti-retroviral activity on immune and hematopoietic functions in mice: In vitro toxicity to precursor cells and microstromal environment
19. Effect of nucleoside analogs on neurite regeneration and mitochondrial DNA synthesis in PC-12 cells
20. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity
21. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis
22. The intracellular phosphorylation of (-)-2′-deoxy-3′-thiacytidine (3TC) and the incorporation of 3TC 5′-monophosphate into DNA by HIV-1 reverse transcriptase and human DNA polymerase gamma
23. Removal of anti-human immunodeficiency virus 2′,3′-dideoxynucleoside monophosphates from DNA by a novel human cytosolic 3′-5′ exonuclease
24. Cytotoxicity of 3′-azido-3′-deoxythymidine correlates with 3′-azidothymidine-5′-monophosphate (AZTMP) levels, whereas anti-human immunodeficiency virus (HIV) activity correlates with 3′-azidothymidine-5′-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells
25. Characterization of a dCTP transport activity reconstituted from human mitochondria
26. Metabolism, mitochondrial uptake and toxicity of 2′,3′-dideoxycytidine
27. Mitochondrial injury. Lessons from the fialuridine trial
28. Phosphorylation of the anti-hepatitis B nucleoside analog 1-(2′-deoxy-2′-fluoro-1-beta-D- arabinofuranosyl)-5-iodouracil (FIAU) by human cytosolic and mitochondrial thymidine kinase and implications for cytotoxicity
29. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides
30. Cellular pharmacology of 2′,3′- dideoxy-2′,3′-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus
31. Expression of human mitochondrial thymidine kinase in Escherichia coli: Correlation between the enzymatic activity of pyrimidine nucleoside analogues and their inhibitory effect on bacterial growth
32. Enhanced cytotoxicity of nucleoside analogs by overexpression of mitochondrial deoxyguanosine kinase in cancer cell lines
33. The human mitochondrial deoxynucleotide carrier and its role in the toxicity of nucleoside antivirals
34. Favorable interaction of beta-L(-) nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of human immunodeficiency virus
35. Metabolism of 2′,3′-dideoxy-2′,3′-didehydro-beta-L(-)-5- fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro
36. Susceptibility of HIV-1-TAT transfected cells to undergo apoptosis. Biochemical mechanisms
37. Control of mitochondrial membrane permeabilisation by adenine nucleotide translocator interacting with HIV-1 viral protein R and Bcl-2
38. Mitochondrial toxicity of antiviral drugs
39. Review article: The influence of human immunodeficiency virus-1 on hematopoiesis
40. Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy
41. Filgrastim to treat neutropenia and support myelosuppressive medication dosing in HIV infection. G-CSF 92105 Study Group
42. Effect of blood substitute, recombinant hemoglobin, on in vivo hematopoietic recovery from AZT toxicity
43. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials [see comments]
44. Antiviral nucleoside toxicity in canine bone marrow progenitor cells and its relationship to drug permeation
45. Effects of 2′,3′-dideoxynucleosides on proliferation and differentiation of human pluripotent progenitors in liquid culture and their effects on mitochondrial DNA synthesis
46. Causes of macrocytosis in HIV-infected patients not treated with zidovudine
47. Ineffective platelet production in thrombocytopenic human immunodeficiency virus-infected patients
48. Treatment of human immunodeficiency virus-related thrombocytopenia with zidovudine
49. Myopathy and HIV infection
50. Mitochondrial myopathy caused by long-term zidovudine therapy
51. Myopathies associated with human immunodeficiency virus and zidovudine: Can their effects be distinguished?
52. Analysis of myopathy in a placebo-controlled zidovudine trial
53. Neuromuscular function in HIV infection: Analysis of a placebo-controlled combination antiretroviral trial
54. Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells
55. Clinical, histological and molecular reversibility of zidovudine myopathy
56. HIV or zidovudine myopathy
57. Cytochrome c oxidase reaction improves histopathological assessment of zidovudine myopathy
58. Mitochondrial myopathies
59. Zidovudine-induced experimental myopathy: Dual mechanism of mitochondrial damage
60. Simvastatin-induced rhabdomyolysis in an HIV-infected patient with coronary artery disease
61. Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV-positive patients
62. Cardiac manifestations of HIV/AIDS: A review of disease spectrum and clinical management
63. Mitochondria and heart disease
64. Cardiac mitochondrial DNA polymerase-gamma is inhibited competitively and noncompetitively by phosphorylated zidovudine
65. Mitochondrial ultrastructural and molecular changes induced by zidovudine in rat hearts
66. Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudine
67. Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovudine
68. Absence of cardiac toxicity of zidovudine in infants - Reply
69. Cardiomyopathy associated with antiretroviral therapy in patients with HIV infection: A report of six cases
70. Dilated cardiomyopathy in HIV-infected patients
71. HIV-associated peripheral neuropathy
72. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection
73. Peripheral neuropathy with nucleoside antiretrovirals: Risk factors, incidence and management
74. Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea
75. A retrospective study to determine if hydroxyurea augmentation of antiretroviral drug regimens that contain ddI and/or d4T increases the risk of developing peripheral neuropathy in HIV-1 infected individuals
76. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection
77. Efficacy of a vibratory stimulus for the relief of HIV-associated neuropathic pain
78. A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy
79. Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues
80. Immunohistochemical quantification of cutaneous innervation in HIV-associated peripheral neuropathy: A study of L-acetyl-carnitine therapy
81. Topical application of aspirin/diethyl ether in treatment of painful distal sensory polyneuropathy in HIV-positive individuals: A randomized, double-blind, crossover placebo-controlled study
82. Schwann cell mitochondrial alterations in peripheral nerves of rabbits treated with 2′,3′-dideoxycytidine
83. Didanosine (ddl) and stavudine (d4T): Absence of peripheral neurotoxicity in rabbits
84. Neuropathy associated with mitochondrial disorders
85. Acute pancreatitis in human immunodeficiency virus-infected patients: A review
86. Acute pancreatitis as a common complication of 2′,3′-dideoxyinosine therapy in the acquired immunodeficiency syndrome
87. Acute pancreatitis
88. Randomized trial of continued indinavir (IDV)/ZDV/3TC vs Switch to IDV/ddI/d4T or IDV/ddI/d4T + hydroxyurea in patients with viral suppression
89. Incidence of pancreatitis in HIV-infected patients on nucleoside RTIs
90. Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection
91. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection
92. Altered residual ATP content in rat brain cortex subcellular fractions following status epilepticus induced by lithium and pilocarpine
93. Acute pancreatitis with severe lactic acidosis in an HIV-infected patient on didanosine therapy
94. Pearson's marrow-pancreas syndrome. A multisystem mitochondrial disorder in infancy
95. In vivo and in vitro effects of the azidothymidine analog dideoxyinosine on the exocrine pancreas of the rat
96. A convenient assay for in vitro evaluation of mitochondrial toxicity of antiretroviral drugs
97. Ritonavir, triglycerides and pancreatitis
98. Hepatomegaly with severe steatosis in HIV-seropositive patients
99. Fatal lactic acidosis and liver steatosis associated with didanosine and stavudine treatment: A respiratory chain dysfunction?
100. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion
101. Optimal handling of blood samples for routine measurement of lactate and pyruvate
102. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens
103. Incidence and outcome of hyperlactatemia associated with clinical manifestations in HIV-infected adults receiving NRTI-containing regimens
104. Symptomatic hyperlactatemia: An emerging complication of antiretroviral therapy
105. Lactic acidosis complicating antiretroviral therapy: Frequency and correlates
106. Chronic hyperlactaemia in HIV-infected patients taking antiretroviral therapy
107. Hyperlactatemia and antiretroviral therapy in the Swiss HIV Cohort Study (SHCS)
108. Hyperlactatemia in HIV-infected patients: The role of NRTI treatment
109. Differences in anion gap with different nucleoside RTI combinations
110. Early diagnosis of lactic acidosis in HIV-infected adults receiving antiretrovirals: Anion gap measurement
111. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy contribution to protease inhibitor-related lipodystrophy syndrome
112. The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy
113. Reversibility of peripheral fat wasting (lipoatrophy) on stopping stavudine therapy
114. Lipodystrophy and metabolic abnormalities in a cross-sectional study of participants in randomised controlled studies of combination antiretroviral therapy
115. Treatment of nucleoside reverse transcriptase inhibitor-induced lactic acidosis
116. A controlled clinical trial of dichloroacetate for treatment of lactic acidosis in adults
117. Lactic acidosis in the setting of antiretroviral therapy for the acquired immunodeficiency syndrome - A case report and review of the literature
118. Lipodystrophies
119. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
120. Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy
121. Metabolic side effects of anti-retroviral therapy in the Swiss cohort study
122. Lipodystrophy in PI-naive patients treated with RTI combinations: Frequency and risk factors
123. Incidence of fat tissue abnormalities in protease inhibitor-naive patients treated with NRTI combinations
124. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study
125. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
126. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy
127. Estradiol levels and lipodystropy in HIV+ men
128. Risk factors for HIV-associated lipodystrophy syndrome in patients with uniform duration of antiretroviral treatment (LipART)
129. Clinical factors related to the severity of fat redistribution in the HIV Outpatient Study (HOPS)
130. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection
131. A cohort study of lipodystrophy in HIV-infected patients treated with HAART
132. Risk of developing adipose tissue alterations after starting antiretroviral therapy in naive patients
133. Factors related to the presence of fat redistribution in HIV-infected patients treated with protease inhibitor-containing regimens, APROCO cohort, 1999
134. Risk of lipodystrophy in HIV-1 infected patients treated with protease inhibitors: A prospective cohort study
135. Risk factors associated with types of metabolic and morphological alterations according to the Marrakech classification
136. No difference in lipodystrophy incidence in stavudine versus zidovudine nucleoside backbone: Blinded evaluation in a cohort on first line HAART
137. Prevalence of lipodystrophy in the long-term follow-up of a clinical trial comparing various combinations of nucleoside analogue reverse transcriptase inhibitors, ALBI Trial (ANRS 070)
138. Assessment of lipodystrophy in patients previously exposed to AZT, ddI or ddC, but naive for d4T and protease inhibitors (PI), and randomized between d4T/3TC/indinavir and AZT/3TC/indinavir (NOVAVIR Trial)
139. Incidence of lipodystrophy in START (selection of thymidine analog regimen therapy) studies
140. Contribution of NRTIs Combinations on Lipodystrophy and Impact of Therapy Switching
141. Improvement in facial lipoatrophy after substitution of stavudine
142. Decrease of mitochondrial DNA content in adipose tissue of HIV-1 infected patients treated with NRTIs
143. Analysis of subcutaneous adipose tissue mitochondrial DNA from individuals with HAART-associated lipodystrophy
144. Light and electron microscopy findings in subcutaneous fat in antiretroviral treated and naive HIV-infected patients
145. Anti-oxidants rescue NRTI-induced metabolic changes in AKR/J mice
146. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: A randomized controlled trial
147. Cytotoxicity of antiviral nucteotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1
148. Mitochondrial disorders and the kidney
149. Kinetic interaction of the diphosphates of 9-(2-phosphonylmethoxyethyl)adenine and other anti-HIV active purine congeners with HIV reverse transcriptase and human DNA polymerases alpha, beta and gamma
150. Dideoxyinosine-associated nephrotoxicity [letter]
151. Renal tubular acidosis and hypophosphataemia after treatment with nucleoside reverse transcriptase inhibitors
152. Persistent mitochondrial dysfunction and perinatal exposure to antiviral nucleoside analogues
153. Mitochondrial and mitochondrial-like symptoms in children born to HIV-infected mothers. Exhaustive evaluation in a large prospective cohort
154. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: Absence of clear evidence of mitochondrial disease in children who died before 5 years of age in five United States cohorts
155. Lack of definitive severe mitochondrial signs and symptoms among deceased HIV-uninfected and HIV-indeterminate children <5 years of age, pediatric spectrum of disease project (PSD), USA
156. Drug safety during pregnancy and in infants: Lack of mortality related to mitochondrial dysfunction among perinatally HIV-exposed children in pediatric HIV surveillance
157. Lack of evidence of mitochondrial dysfunction in the offspring of HIV-infected women
158. Perinatal exposure to zidovudine - Benefits and risk
159. Treatment of mitochondrial disease
160. Depletion of mitochondrial DNA, destruction of mitochondria, and accumulation of lipid droplets result from fialuridine treatment in woodchucks (Marmota monax)
161. Effect of anti-HIV 2′-beta-fluoro-2′,3′-dideoxynucleoside analogs on the cellular content of mitochondrial DNA and on lactate production
162. Multi-center randomized phase II trial of multiple doses of lodenosine (FddA) in combination with stavudine and indinaavir in antiretroviral naive HIV-infected adult patients
163. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity
164. Abacavir safety and tolerability: Experience from over 25,000 adults and children
165. Abacavir - A review of its clinical potential in patients with HIV infection [Review]
166. Risk factors for the HIV-associated lipodystrophy syndrome in a cross-sectional single-centre study